MAPT and Alzheimer disease: As AD is a multifactorial disease, targeting AD-associated processes like tau-associated pathology, inflammatory responses, synaptic activity, and neuroepigenetic regulation of AD-related genes may provide alternative therapeutic strategies during early AD progression.